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Introduction: Hemodialysis (HD) and peritoneal dialysis (PD) are commonly used to treat 
patients with end-stage renal disease (ESRD). However, their costs have grown considerably 
in recent years as the rates of non-communicable diseases including diabetes and 
hypertension have grown. This will adversely impact on national health budgets especially in 
LMICs. Currently, there is limited knowledge about the costs of ESRD and the different 
components within the public healthcare system in South Africa. Consequently, our objective 
was to examine the direct medical costs of both approaches from a public provider 
perspective to provide future guidance. Methods: A prospective observational study 
undertaken at a leading public hospital in South Africa based principally on patients’ notes 
and costs from nationally procured lists. A micro-costing approach was used to estimate 
health care costs among adult patients with ESRD who had received either HD and PD for at 
least 3 months. Results: The majority of patients (35%) were aged 40 to 50 years. Patients 
aged 29-39 years were mostly on HD (28%) while those between 51-59 years mostly on PD 
(29%), with HD typically managed in the private sector with limited facilities in the public 
sector. The average age of patients on HD and PD were 41 and 42 years respectively. 
Variable costs (HD; US$172, 359.15, PD; US$20, 488.79) were the highest cost component 
for both HD and PD patients. The annual cost of HD (US$205,681.4) was higher than PD 
(US$25,282 per patient) even though the difference was not statistically significant (p = 
0.175). The overall burden if appreciably more patients with ESRD are managed 
appropriately within the public system (covering 80% of the population) would be 
considerable and become unaffordable. Conclusion: HD costs more than PD. These cost 
estimates are useful for carrying out future health economic analyses and for allocating 
greater resources to prevent progress to ESRD. 
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